| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2022 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.